T-cell Engagers (CD3 Bispecifics)

Cat. No.

AT0016

CAS No.

2119595-80-9

Teclistamab

Teclistamab is a human bispecific antibody that simultaneously targets B cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells. By engaging both cell types, Teclistamab induces T cell activation and redirects cytotoxic responses toward BCMA-expressing cells. This bispecific format is widely used in preclinical models of multiple myeloma to study T cell–mediated antitumor activity and immune cell redirection strategies.

Cat. No.

AT0017

CAS No.

2251756-52-0

Pacanalotamab

Synonyms: AMG 420; BI-836909

Pacanalotamab is a bispecific T-cell engager (BiTE®) antibody construct targeting B cell maturation antigen (BCMA) and CD3ε. By bridging T cells and BCMA-expressing multiple myeloma cells, Pacanalotamab promotes potent T cell–mediated cytotoxicity. It is a valuable tool for preclinical evaluation of immune cell redirection and targeted therapies in hematologic malignancies.

Cat. No.

AT0035

CAS No.

876387-05-2

Teplizumab

Synonyms: MGA-031; PRV-031

Teplizumab is a humanized Fc receptor–nonbinding anti-CD3 monoclonal antibody that modulates T cell function and reduces β-cell destruction. It is commonly used in preclinical and clinical research focused on autoimmune diabetes, particularly in delaying or preventing the onset of type 1 diabetes.

Cat. No.

AT0086

CAS No.

2229047-91-8

Glofitamab

Synonyms: RO7082859

Glofitamab (RO7082859) is a bispecific antibody designed for targeted cancer immunotherapy, featuring a unique 2:1 architecture that incorporates dual binding sites for CD20 on B cells and a single binding site for CD3 on T cells. This configuration facilitates the selective engagement and activation of T cells, which then proliferate and exert cytotoxic effects on malignant cells expressing CD20. Clinically, Glofitamab has demonstrated the capacity to induce durable complete remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), highlighting its potential as a therapeutic agent in hematologic oncology.

Cat. No.

AT0129

CAS No.

2640279-10-1

Zubotamig

Synonyms: Gen1047

Zubotamig is a chimeric human antibody of the IgG1κ subtype that specifically targets CD3E and VTCN1. This monoclonal antibody is engineered for precise binding affinity to these antigens, making it an invaluable tool for research into T-cell activation and immune regulation. Suitable for a variety of immunological assays, Zubotamig facilitates advanced studies in immunotherapy and autoimmune disease mechanisms.

Cat. No.

AT0151

GEN-1044

GEN-1044 is a bispecific antibody targeting CD3 and the oncofetal antigen 5T4. This antibody exhibits dual functionality by engaging both the immune system's T cells and the tumor-associated antigen 5T4, thereby facilitating immunomodulatory and antineoplastic activities. This specificity makes GEN-1044 a valuable tool for research in cancer immunotherapy, particularly in studies focused on the mechanisms of T-cell mediated tumor rejection.

Cat. No.

AT0165

CAS No.

1005198-65-1

Solitomab

Synonyms: AMG 110; MT110

Solitomab (AMG 110) is a bispecific antibody designed to target both CD3, a T-cell co-receptor, and Epithelial Cell Adhesion Molecule (EpCAM), which is frequently overexpressed in various carcinomas. This dual targeting mechanism facilitates the redirection of T cells to EpCAM-expressing tumor cells, promoting T-cell mediated cytotoxicity. Solitomab is primarily utilized in research focused on primary uterine and ovarian carcinosarcoma, providing a valuable tool for investigating the therapeutic potential of bispecific antibodies in cancer immunotherapy.

Cat. No.

AT0171

CAS No.

2408319-33-3

Vonsetamig

Vonsetamig is a bispecific antibody comprising humanized immunoglobulin G4-kappa that targets both TNFRSF17 and CD3E. This therapeutic antibody is designed to act as an antineoplastic agent, leveraging its dual specificity to modulate immune system responses against cancer cells. Vonsetamig's unique ability to bind to both a tumor necrosis factor receptor superfamily member 17 (TNFRSF17) on malignant cells and the CD3 epsilon (CD3E) on T-cells facilitates a directed immune response towards the tumor environment, making it a critical tool in cancer immunotherapy research.

Cat. No.

AT0193

CAS No.

2736407-54-6

Brenetafusp

Brenetafusp is a monoclonal antibody designed to target both CD3E and PRAME. This dual-targeting approach enhances its potential for use in the selective elimination of tumor cells while engaging the immune system via the CD3E component. Brenetafusp holds significant promise for therapeutic applications in oncology, particularly in treatments aimed at PRAME-expressing malignancies.

Cat. No.

AT0207

CAS No.

2839556-21-5

Mipletamig

Mipletamig is a chimeric antibody comprising both human and humanized elements, specifically designed to target CD3E. Its structure includes a [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 format, integrating single-chain variable fragments (scFv) linked to the constant regions of human immunoglobulin G1 heavy chains (CH2-CH3). This antibody is engineered for high specificity and affinity toward CD3E, making it an invaluable tool in immunological research and therapeutic development.

Cat. No.

AT0212

CAS No.

2069959-72-2

Obrindatamab

Synonyms: MGD009

Obrindatamab is a humanized bispecific antibody that targets both B7-H3 and CD3. By binding to these molecules, Obrindatamab facilitates the redirection of cytotoxic T-lymphocyte (CTL) activity towards cancer cells expressing B7-H3. This antibody is utilized primarily in cancer research to study immune-mediated tumor cell eradication.

Cat. No.

AT0214

CAS No.

2305629-50-7

Ubamatamab

Synonyms: REGN4018

Ubamatamab (REGN4018) is a humanized bispecific antibody that specifically targets Mucin 16 (MUC16) and CD3. This antibody has demonstrated potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Ubamatamab engages both tumor cells expressing MUC16 and T-cells via CD3, facilitating an immune response against the tumor cells. This dual targeting mechanism is critical for its application in studies focused on ovarian and other MUC16-positive cancers.

Cat. No.

AT0215

CAS No.

2851943-09-2

Obrixtamig

Synonyms: BI 764532; OBT 620

Obrixtamig is a chimeric human antibody designed to target CD3E and HEK. It is comprised of both kappa (κ) and lambda (λ) light chains and includes the human G1 heavy chain constant regions (CH2-CH3). This dual specificity and structural composition enhance its applicability in various immunological research settings, focusing on the modulation of T-cell activity and potential cellular engineering studies.

Cat. No.

AT0278

CAS No.

2885203-43-8

Linclatamig

Linclatamig is a humanized IgG1κ monoclonal antibody that specifically targets CD3E. For isotype control, Human IgG1 kappa Isotype Control is recommended. This antibody is designed for precise targeting, making it ideal for research applications focusing on CD3E-related pathways and immune responses.

Cat. No.

AT0309

CAS No.

1679391-73-1

Eluvixtamab

Synonyms: AMG-330

Eluvixtamab is a monoclonal antibody that targets both CD3E and CD33 antigens. This dual specificity enables it to engage T cells and myeloid cells simultaneously, making it a valuable tool for research into immune cell interactions and potential therapeutic applications in diseases characterized by aberrant myeloid cell activity.

Cat. No.

AT0314

CAS No.

2361325-98-4

Runimotamab

Runimotamab is a chimeric humanized antibody of the IgG1-κ isotype, designed to specifically target CD3E and HER2 receptors. This dual targeting strategy enhances the antibody's ability to mediate immune responses against cells expressing HER2, a receptor tyrosine kinase implicated in the progression of several forms of cancer, including breast and gastric cancers. Runimotamab's engagement of CD3E on T cells potentially facilitates a more direct and potent cytotoxic response, making it a valuable tool for research in cancer immunotherapy and the study of bispecific antibody mechanisms.

Cat. No.

AT0380

CAS No.

2226212-40-2

Talquetamab

Synonyms: JNJ-64407564

Talquetamab (JNJ-64407564) is a humanized bispecific antibody engineered to target GPRC5D, a member of the G protein-coupled receptor family C group D, and CD3, a key component in T-cell activation. This antibody facilitates the recruitment and activation of T cells, leading to the selective killing of multiple myeloma (MM) cells expressing GPRC5D. Demonstrating significant antitumor activity, Talquetamab is pivotal in advancing therapeutic strategies for MM treatment through its dual targeting mechanism.

Cat. No.

AT0412

CAS No.

2296827-07-9

Alnuctamab

Synonyms: EM901; CC-93269

Alnuctamab (EM901) is a humanized, asymmetric two-arm immunoglobulin G (IgG) T-cell engager (TCE) designed to facilitate targeted immune responses. This bi-specific antibody selectively binds to the B-cell maturation antigen (BCMA) and CD3, a critical component of the T-cell receptor complex. Alnuctamab is primarily utilized in immunological research to study and manipulate T-cell mediated responses against cells expressing BCMA, making it a valuable tool in the investigation of immune therapies.

Cat. No.

AT0436

CAS No.

853426-35-4

Blinatumomab

Synonyms: Anatumomab; bscCD19xCD3

Blinatumomab, also known as Anatumomab, is a bispecific monoclonal antibody designed to simultaneously engage two distinct epitopes: CD3E on T cells and CD19 on B cells. This unique dual-binding capability facilitates the redirection of T cells to target and eliminate CD19-expressing B cells. Blinatumomab is primarily utilized in research focused on the treatment and understanding of acute lymphoblastic leukemia (ALL), offering significant insights into therapeutic strategies and disease management.

Cat. No.

AT0440

CAS No.

2250292-39-6

Pavurutamab

Synonyms: AMG-701

Pavurutamab (AMG-701) is a bispecific T-cell engager that targets both CD3 on T-cells and B-cell maturation antigens (BCMA) on plasma cells. This molecule is engineered with an extended half-life derivative of Pacanalotamab, enhancing its stability and duration of action. The Fc region of Pavurutamab has been modified to incorporate molecules that optimize its pharmacokinetic properties, ensuring sustained efficacy. This biologic is primarily investigated for its potential therapeutic applications in the modulation of immune responses and as a treatment for multiple myeloma (MM).

Cat. No.

AT0445

CAS No.

2851862-91-2

Gocatamig

Synonyms: MK-6070; HPN328

Gocatamig is a chimeric humanized antibody designed with a single-chain variable fragment-heavy-lambda (scFv-heavy-lambda)-VH-VH' configuration. It specifically targets CD3E, ALB, and DLL3, making it suitable for advanced research applications that investigate cellular processes involving these proteins. This antibody's unique structure and specificity are ideal for studies in immunology and oncology, particularly in the modulation of immune responses and the investigation of cancer cell dynamics.

Cat. No.

AT0464

CAS No.

2250261-27-7

Emerfetamab

Synonyms: AMG-673

Emerfetamab is a monoclonal antibody designed to target both CD3E and CD33 molecules. This dual specificity enables it to engage T cells via CD3E and simultaneously recognize myeloid cells through CD33, making it a valuable tool in the research of immune cell interactions and potential therapeutic applications in hematological malignancies.

Cat. No.

AT0475

CAS No.

219716-33-3

Visilizumab

Synonyms: Anti-Human CD3E Recombinant Antibody; HuM291

Visilizumab is a humanized monoclonal IgG2 antibody with low Fc receptor binding affinity, targeting CD3E. This recombinant antibody is designed for the study of immune-mediated gastrointestinal disorders, including ulcerative colitis and Crohn's disease. Its specificity for CD3E makes it a valuable tool in research focused on T-cell mediated responses in these conditions.

Cat. No.

AT0498

CAS No.

509077-98-9

Catumaxomab

Catumaxomab is a trifunctional IgG2 antibody engineered from mouse and rat heavy and light chains. This antibody exhibits specific binding to human epithelial cell adhesion molecule (EpCAM) and the T-cell receptor CD3. Additionally, the Fc region of Catumaxomab demonstrates affinity for Fc gamma receptors FcγR1 (CD64), FcγRIIA (CD32a), and FcγRIII (CD16). Due to its unique binding properties, Catumaxomab is particularly valuable in the study of epithelial cancers, serving as a potent tool in anti-tumor research applications.

Cat. No.

AT0567

CAS No.

2044679-53-8

Tepoditamab

Synonyms: MCLA 117

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody engineered to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A is recognized as a myeloid differentiation antigen. This antibody facilitates the targeted destruction of both acute myeloid leukemia (AML) progenitor and stem cells. It achieves this through the induction of T cell-mediated cytotoxicity, leading to the proliferative lysis of AML cells. Tepoditamab (MCLA-117) is particularly valuable for research focused on the mechanisms and therapeutic interventions of acute myeloid leukemia.